To All Patients:
Please realize that due to HIPPA restrictions, we are unable to reply to any social media communications (i.e., Facebook, e-mail, etc) containing ANY of your medical information. Please do not send such communiques by any of these methods, as we are unable to respond. This is to protect your privacy. Please call the office at 334-475-2058 for such concerns.
Due to inclement weather forecasts, the office will be closed Jan 30, 2019: we will re-open Thurs morning. Please stay warm and safe.
IMPORTANT UPDATE FOR ALL FAA APPLICANTS
NEW CHANGES IN CONTROLLED PRESCRIPTION RULES IN ALABAMA
On March 9, 2017, the Alabama Board of Medical Examiners adopted a new rule concerning the use of risk and abuse mitigation strategies for prescribing physicians. The new rule requires the use of risk and mitigation strategies (RMS) when prescribing controlled substances for the treatment of pain. The rule also notes a heightened risk of adverse events associated with concurrent use of opioids and benzodiazepines and requires that physicians reconsider existing benzodiazepine prescriptions. For the purpose of preventing controlled substance diversion, abuse, misuse, addiction, and doctor-shopping, physicians are required to adhere to monitoring requirements utilizing the Alabama Prescription Drug Monitoring Program. It is anticipated that over time, current laws may become even more restrictive. One only has to look at current laws enacted in Ohio as an example, which limit the number of days for which certain prescriptions may be written.
It is the intent of this office to comply with all rules promulgated by the State of Alabama and the Board of Medical Examiners. We recognize that this may necessitate changes to current medical therapy being received and/or consultations to other specialists, such as Pain Management, to meet the new standards while providing for pain mitigation. We regret any hardship this may create, and appreciate your understanding and cooperation during this time of transition.